Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Decrease in Short Interest

Posted by Tyrone Williams on Apr 3rd, 2025

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 70,200 shares, a decrease of 16.9% from the February 28th total of 84,500 shares. Based on an average daily volume of 415,800 shares, the short-interest ratio is currently 0.2 days. Currently, 2.6% of the shares of the company are sold short.

Theriva Biologics Stock Performance

Shares of TOVX stock traded down $0.02 during mid-day trading on Thursday, hitting $1.16. 9,179 shares of the stock were exchanged, compared to its average volume of 994,939. The company has a market capitalization of $3.22 million, a P/E ratio of -0.04 and a beta of 1.22. The stock’s fifty day moving average price is $1.36. Theriva Biologics has a 52-week low of $1.03 and a 52-week high of $12.28.

Institutional Trading of Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP acquired a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). 6.17% of the stock is currently owned by institutional investors.

About Theriva Biologics

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.